Rhythm Pharmaceuticals
RYTM
112.36
-4.44
-3.80%
Rhythm Pharmaceuticals
US · RYTM
#1874 by market cap
Listed 2017
112.36
-4.44
-3.80%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 15 in the most recent period (2026/Q3).
- Total institutional ownership rose 1.9 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 116.11% +1.91pp
- Institutions
- 406 +15
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund71.93%
Hedge Fund18.70%
VC/PE Fund16.04%
Public Company4.84%
Private Company2.37%
Sovereign Wealth Fund0.99%
Individual/Insider0.78%
Government Pension Fund0.60%
Family Office/Trust0.34%
Top holders as of 2026-06-30
RA Capital Management, L.P.
9.62% · 6.67M sh
BlackRock
8.62% · 5.98M sh
Baker Bros. Advisors LP
8.08% · 5.60M sh
PRIMECAP Management Company
4.57% · 3.17M sh
Vanguard Portfolio Management, LLC
4.54% · 3.15M sh
Vanguard Capital Management, LLC
4.33% · 3.01M sh
State Street Global Advisors
3.81% · 2.64M sh
Perceptive Advisors LLC
3.73% · 2.59M sh
T. Rowe Price Group, Inc.
3.70% · 2.57M sh
J.P. Morgan Asset Management, Inc.
3.69% · 2.56M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 28 buys · 22 sells
| Name | Role | Stake |
|---|---|---|
| David Meeker | Chairperson & CEO | 0.35% |
| Hunter Smith | Chief Financial Officer | 0.16% |
| Yann Mazabraud | Executive VP & Head of International | 0.08% |
| Pamela Cramer | Former Chief Human Resources Officer | 0.04% |
| Edward Mathers | Former Lead Independent Director | 0.03% |
| Joseph Shulman | Chief Technology Officer | 0.02% |
| Stuart Arbuckle | Independent Director | 0.02% |
| Christophe Jean | Independent Director | 0.02% |
| David W. McGirr | Independent Director | 0.02% |
| Jennifer Good | Independent Director | 0.02% |
| Lynn Tetrault | Lead Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-13 | David Meeker | Chairperson & CEO | Derivative Exercise and Sale | -50,000 | $6.05–105.19 |
| 2026-08-30 | Hunter Smith | Chief Financial Officer | Automatic Disposition | -5,587 | $106.20 |
| 2026-08-30 | Hunter Smith | Chief Financial Officer | Derivative Exercise and Sale | -57,187 | $25.79–106.20 |
| 2026-08-16 | Manher Joshi | Chief Medical Officer | Other Derivative Acquisition | +25,000 | -- |
| 2026-08-16 | Manher Joshi | Chief Medical Officer | Other Derivative Acquisition | +50,000 | $115.44 |
| 2026-08-12 | Joseph Shulman | Chief Technology Officer | Automatic Disposition | -3,055 | $119.75 |
| 2026-08-12 | Joseph Shulman | Chief Technology Officer | Derivative Exercise and Sale | -2,024 | $6.80–119.75 |
| 2026-08-12 | Alastair Garfield | Chief Scientific Officer | Automatic Disposition | -7,763 | $116.11–119.17 |
| 2026-08-12 | Jennifer Lee | Executive VP & Head of North America | Automatic Disposition | -19,233 | $117.38 |
| 2026-08-12 | Jennifer Lee | Executive VP & Head of North America | Derivative Exercise and Sale | -56,601 | $6.80–117.38 |
| 2026-08-11 | Yann Mazabraud | Executive VP & Head of International | Automatic Disposition | -10,375 | $117.47 |
| 2026-08-11 | Yann Mazabraud | Executive VP & Head of International | Derivative Exercise and Sale | -46,625 | $6.80–117.47 |
| 2026-08-10 | Pamela Cramer | Former Chief Human Resources Officer | Intent to Sell (Form 144) | -11,406 | $115.48 |
| 2026-08-09 | Pamela Cramer | Former Chief Human Resources Officer | Intent to Sell (Form 144) | -3,520 | $115.63 |
| 2026-06-30 | Alastair Garfield | Chief Scientific Officer | Derivative Exercise and Sale | -2,150 | $110.41 |
| 2026-06-30 | Alastair Garfield | Chief Scientific Officer | Derivative Exercise and Retained | +2,295 | -- |
| 2026-06-23 | Jennifer Good | Independent Director | Other Derivative Acquisition | +2,324 | -- |
| 2026-06-23 | Jennifer Good | Independent Director | Other Derivative Acquisition | +3,691 | $107.55 |
| 2026-06-23 | David W. McGirr | Independent Director | Other Derivative Acquisition | +2,324 | -- |
| 2026-06-23 | David W. McGirr | Independent Director | Other Derivative Acquisition | +3,691 | $107.55 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Rhythm Pharmaceuticals discussion 0 comments